{"entity":{"id":"nct06799065","kind":"trial","name":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer","aka":[],"tldr":"A phase 1/2 trial of ATX-295 run by Accent Therapeutics, now recruiting.","summary":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer is a phase 1/2 interventional study registered as NCT06799065 by Accent Therapeutics, with 218 participants planned, started 2025-03-21. Conditions recorded: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC and Squamous Non-small-cell Lung Cancer. Interventions recorded: ATX-295 and ATX-295 and bevacizumab (or biosimilar).","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06799065","url":"https://clinicaltrials.gov/study/NCT06799065"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","breast-cancer","ovarian","tnbc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["atx-295"],"companies":["accent-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06799065","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer","sponsor":"Accent Therapeutics","enrolled":218,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06799065/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"atx-295","kind":"drug","name":"ATX-295","route":"/drugs/atx-295/"}],"company":[{"id":"accent-therapeutics","kind":"company","name":"Accent Therapeutics","route":"/companies/accent-therapeutics/"}]}}